- Home
- ONIT vs ZNTL Comparison
ONIT vs ZNTL Comparison
Compare ONIT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONIT
- ZNTL
- Stock Information
- Founded
- ONIT 1988
- ZNTL 2014
- Country
- ONIT United States
- ZNTL United States
- Employees
- ONIT N/A
- ZNTL N/A
- Industry
- ONIT
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ONIT
- ZNTL Health Care
- Exchange
- ONIT NYSE
- ZNTL Nasdaq
- Market Cap
- ONIT 308.3M
- ZNTL 105.8M
- IPO Year
- ONIT 1996
- ZNTL 2020
- Fundamental
- Price
- ONIT $38.67
- ZNTL $1.26
- Analyst Decision
- ONIT Strong Buy
- ZNTL Buy
- Analyst Count
- ONIT 2
- ZNTL 7
- Target Price
- ONIT $52.50
- ZNTL $8.60
- AVG Volume (30 Days)
- ONIT 38.7K
- ZNTL 1.3M
- Earning Date
- ONIT 07-31-2025
- ZNTL 08-08-2025
- Dividend Yield
- ONIT N/A
- ZNTL N/A
- EPS Growth
- ONIT 248.50
- ZNTL N/A
- EPS
- ONIT 2.98
- ZNTL N/A
- Revenue
- ONIT $986,700,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- ONIT $7.68
- ZNTL N/A
- Revenue Next Year
- ONIT $9.23
- ZNTL N/A
- P/E Ratio
- ONIT $12.97
- ZNTL N/A
- Revenue Growth
- ONIT N/A
- ZNTL N/A
- 52 Week Low
- ONIT $22.40
- ZNTL $1.01
- 52 Week High
- ONIT $41.27
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- ONIT 58.69
- ZNTL 45.95
- Support Level
- ONIT $37.20
- ZNTL $1.13
- Resistance Level
- ONIT $37.99
- ZNTL $1.39
- Average True Range (ATR)
- ONIT 1.22
- ZNTL 0.11
- MACD
- ONIT 0.06
- ZNTL -0.02
- Stochastic Oscillator
- ONIT 84.26
- ZNTL 31.71
About ONIT ONITY GROUP INC
Onity Group Inc is a non-bank mortgage servicer and originator providing solutions through its brands, PHH Mortgage and Liberty Reverse Mortgage. PHH Mortgage is one of the servicers in the country, focused on delivering a variety of servicing and lending programs. Liberty is one of the nation's reverse mortgage lenders dedicated to education and providing loans that help customers meet their personal and financial needs.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.